RESUMEN
Zika fever is an acute infectious disease caused by the Zika virus (ZIKV), an RNA virus belonging to the genus Flavivirus. ZIKV can be transmitted by bites from Aedes aegypti and Aedes albopictus species, sexual activity, blood transfusion and from mother to fetus during pregnancy and delivery. A total of 50 territories and countries in the Americas had reported ZIKV infections. For those with symptoms, the presentation is similar to dengue fever with body aches, joint pain, fatigue, malaise, fever and conjunctivitis lasting up to seven days. A maculopapular rash may also occur and is usually pruritic. Neurological complications are well documented and include Guillain-Barré Syndrome (GBS) and congenital ZIKV syndrome, and less frequently acute myelitis and meningoencephalitis. ZIKV infection usually causes a mild illness and most patients are managed conservatively. Currently, no antiviral therapy is available. The most appropriate therapy for ZIKV-associated GBS is yet unclear, however intravenous immunoglobulins have been used, as in conventional GBS. ZIKV infection can be prevented through the use of mosquito repellents, protection with long-sleeved clothing and trousers, and the use of clothes impregnated with permethrin. This review describes the current concepts regarding the epidemiology, diagnosis, clinical manifestations and neurological complications of ZIKV infection.
Asunto(s)
Cuidados Críticos/organización & administración , Síndrome de Guillain-Barré/epidemiología , Infectología/métodos , Infección por el Virus Zika/epidemiología , Virus Zika , Enfermedad Aguda , Comités Consultivos , Antivirales , Dengue/epidemiología , Virus del Dengue , Brotes de Enfermedades , Femenino , Salud Global , Síndrome de Guillain-Barré/complicaciones , Humanos , Meningoencefalitis/complicaciones , Mielitis/complicaciones , Enfermedades del Sistema Nervioso/complicaciones , Enfermedades del Sistema Nervioso/epidemiología , Embarazo , Virus ARN , Sociedades Médicas , Infección por el Virus Zika/complicacionesRESUMEN
Chikungunya is an arbovirus that is transmitted by the Aedes mosquito causing a febrile illness with periodic outbreaks in large parts of the world. In the last decade it has become a public health concern in a host of countries and has affected international tourists. In the vast majority of cases Chikungunya presents as an acute febrile illness, associated with rash, headache, myalgia and debilitating arthralgia or even polyarthritis. A small proportion of patients present atypically with nervous, ocular, renal, myocardial, respiratory and renal system involvement and may require ICU management. Over the years the epidemic potential of the virus has become apparent with spread related to an increase in global travel and the successful adaptation of the Aedes mosquito to the urban and sylvan environments in numerous countries. These epidemics have affected millions of people across the globe. Treatment is usually symptomatic and supportive.
Asunto(s)
Fiebre Chikungunya/epidemiología , Cuidados Críticos/organización & administración , Fiebre/epidemiología , Comités Consultivos , Aedes , Animales , Fiebre Chikungunya/diagnóstico , Fiebre Chikungunya/transmisión , Virus Chikungunya , Brotes de Enfermedades , Epidemias , Geografía , Salud Global , Humanos , Necrosis , Sociedades Médicas , Resultado del TratamientoRESUMEN
Dengue is an arbovirus affecting humans and spread by mosquitoes. Severe dengue follows a secondary infection with a different virus serotype. The problem is truly global as it is endemic in over 100 countries. Severe dengue can be a life-threatening because of increased vascular permeability, resulting in leakage of fluid from the intravascular compartment to the extravascular space. When major bleeding does occur, it is almost invariably combined with profound shock since this, in combination with thrombocytopenia, hypoxia, and acidosis, can lead to multiple organ failure and disseminated intravascular coagulation. Dengue hemorrhagic fever and dengue shock syndrome are among the leading causes of morbidity and mortality in patients suffering from Dengue. Commercial rapid tests and ELISA kits are freely available, ensuring early diagnosis. The basis of management of severe dengue is effective fluid replacement. Future directions in management will involve vector control and development of effective vaccination.
Asunto(s)
Comités Consultivos , Cuidados Críticos , Dengue , Sociedades Médicas , Medicina Tropical , Servicios de Salud Comunitaria , Dengue/diagnóstico , Dengue/prevención & control , Dengue/terapia , Vacunas contra el Dengue , Países en Desarrollo , Pruebas Diagnósticas de Rutina , Diagnóstico Precoz , Recursos en Salud , Humanos , Guías de Práctica Clínica como Asunto , Factores de RiesgoRESUMEN
Leptospirosis is a zoonosis caused by a gram negative aerobic spirochete of the genus Leptospira. It is acquired by contact with urine or reproductive fluids from infected animals, or by inoculation from contaminated water or soil. The disease has a global distribution, mainly in tropical and subtropical regions that have a humid, rainy climate and is also common in travelers returning from these regions. Clinical suspicion is critical for the diagnosis and it should be included in the differential diagnosis of any patient with a febrile hepatorenal syndrome in, or returning from endemic regions. The leptospiremic phase occurs early and thereafter there is an immunologic phase in which the most severe form, Weil's disease, occurs. In the latter, multiple organ dysfunction predominates. The appropriate diagnostic test depends on the stage of the disease and consists of direct and indirect detection methods and cultures. Severely ill patients need to be monitored in an ICU with appropriate anti-bacterial agents and early, aggressive and effective organ support. Antibiotic therapy consists of penicillins, macrolides or third generation cephalosporins.
Asunto(s)
Comités Consultivos , Antibacterianos/uso terapéutico , Cuidados Críticos , Leptospirosis/diagnóstico , Sociedades Médicas , Medicina Tropical , Enfermedad de Weil/diagnóstico , Animales , Cuidados Críticos/normas , Diagnóstico Diferencial , Fiebre/diagnóstico , Humanos , Leptospirosis/terapia , Enfermedad de Weil/terapiaRESUMEN
Viral hemorrhagic fevers (VHFs) are a group of illnesses caused by four families of viruses namely Arenaviruses, Filoviruses, Bunyaviruses, and Flaviviruses. Humans are not the natural reservoir for any of these organisms and acquire the disease through vectors from animal reservoirs. In some conditions human to human transmission is possible increasing the risk to healthy individuals in the vicinity, more so to Health Care Workers (HCW). The pathogenesis of VHF, though poorly understood, varies according to the viruses involved. The resultant microvascular damage leads to increased vascular permeability, organ dysfunction and even death. The management is generally supportive but antiviral agents are of benefit in certain circumstances.
Asunto(s)
Cuidados Críticos/normas , Fiebres Hemorrágicas Virales/diagnóstico , Unidades de Cuidados Intensivos/normas , Evaluación de Resultado en la Atención de Salud , Comités Consultivos , Cuidados Críticos/economía , Países en Desarrollo , Reservorios de Enfermedades/virología , Fiebres Hemorrágicas Virales/terapia , Fiebres Hemorrágicas Virales/virología , Humanos , Unidades de Cuidados Intensivos/economía , Área sin Atención Médica , Sociedades Médicas , Medicina TropicalRESUMEN
BACKGROUND: Little information is available about the geo-economic variations in demographics, management, and outcomes of patients with acute respiratory distress syndrome (ARDS). We aimed to characterise the effect of these geo-economic variations in patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE). METHODS: LUNG SAFE was done during 4 consecutive weeks in winter, 2014, in a convenience sample of 459 intensive-care units in 50 countries across six continents. Inclusion criteria were admission to a participating intensive-care unit (including transfers) within the enrolment window and receipt of invasive or non-invasive ventilation. One of the trial's secondary aims was to characterise variations in the demographics, management, and outcome of patients with ARDS. We used the 2016 World Bank countries classification to define three major geo-economic groupings, namely European high-income countries (Europe-High), high-income countries in the rest of the world (rWORLD-High), and middle-income countries (Middle). We compared patient outcomes across these three groupings. LUNG SAFE is registered with ClinicalTrials.gov, number NCT02010073. FINDINGS: Of the 2813 patients enrolled in LUNG SAFE who fulfilled ARDS criteria on day 1 or 2, 1521 (54%) were recruited from Europe-High, 746 (27%) from rWORLD-High, and 546 (19%) from Middle countries. We noted significant geographical variations in demographics, risk factors for ARDS, and comorbid diseases. The proportion of patients with severe ARDS or with ratios of the partial pressure of arterial oxygen (PaO2) to the fractional concentration of oxygen in inspired air (FiO2) less than 150 was significantly lower in rWORLD-High countries than in the two other regions. Use of prone positioning and neuromuscular blockade was significantly more common in Europe-High countries than in the other two regions. Adjusted duration of invasive mechanical ventilation and length of stay in the intensive-care unit were significantly shorter in patients in rWORLD-High countries than in Europe-High or Middle countries. High gross national income per person was associated with increased survival in ARDS; hospital survival was significantly lower in Middle countries than in Europe-High or rWORLD-High countries. INTERPRETATION: Important geo-economic differences exist in the severity, clinician recognition, and management of ARDS, and in patients' outcomes. Income per person and outcomes in ARDS are independently associated. FUNDING: European Society of Intensive Care Medicine, St Michael's Hospital, University of Milan-Bicocca.